Page 266 - 2021_03-Haematologica-web

912
Letters to the Editor
French Ministry of Health (PRTK 2012-43-CARAMELE). CONECT-AML (COllaborative Network for Children and Teenagers with Acute Myeloid Leukemia) is supported by a grant from InCA, Fondation ARC, Ligue nationale contre le cancer, and Laurette Fugain (InCa-ARC-LIGUE_11905).
References
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
2. Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130(4): 424-432.
3. Tawana K, Wang J, Renneville A, et al. Disease evolution and out- comes in familial AML with germline CEBPA mutations. Blood. 2015;126(10):1214-1223.
4.Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols KE. Stopping leukemia in its tracks: should preemptive hematopoietic stem-cell transplantation be offered to patients at increased genetic risk for acute myeloid leukemia? J Clin Oncol. 2019;37(24):2098-2104.
5. Tawana K, Drazer MW, Churpek JE. Universal genetic testing for inherited susceptibility in children and adults with myelodysplas- tic syndrome and acute myeloid leukemia: are we there yet? Leukemia. 2018;32(7):1482-1492.
6.Duployez N, Martin J-E, Khalife-Hachem S, et al. Germline RUNX1 intragenic deletion: implications for accurate diagnosis of FPD/AML. HemaSphere. 2019;3(3):e203.
7.Drazer MW, Kadri S, Sukhanova M, et al. Prognostic tumor sequencing panels frequently identify germ line variants associat- ed with hereditary hematopoietic malignancies. Blood Adv. 2018;2(2):146-150.
8. Yannakou CK, Jones K, Ryland GL, et al. Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies. J Clin Pathol. 2018;71(1):84-87.
9. Preudhomme C, Renneville A, Bourdon V, et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia second- ary to familial platelet disorder. Blood. 2009;113(22):5583-5587.
10. Marceau-Renaut A, Duployez N, Ducourneau B, et al. Molecular profiling defines distinct prognostic subgroups in childhood AML:
a report from the French ELAM02 study group. HemaSphere.
2018;2(1):e31.
11. Pasquet M, Bellanné-Chantelot C, Tavitian S, et al. High frequen-
cy of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood. 2013;121(5):822-829.
12. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommen- dation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
13. Luo X, Feurstein S, Mohan S, et al. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Adv. 2019;3(20):2962-2979.
14. Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency- associated bone marrow disorder differs from idiopathic aplastic anemia. Blood. 2015;125(1):56-70.
15. Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and related myeloid neoplasms. Semin Hematol. 2017;54(2):81-86. 16.Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological
malignancies. Blood. 2017;129(15):2070-2082.
17. Kohlmann W, Schiffman JD. Discussing and managing hemato-
logic germ line variants. Blood. 2016;128(21):2497-2503.
18. Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and
College of American Pathologists. J Mol Diagn. 2017;19(1):4-23.
19.Davidsson J, Puschmann A, Tedgård U, Bryder D, Nilsson L, Cammenga J. SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies. Leukemia.
2018;32(5):1106-1115.
20. Jongmans MCJ, Loeffen JLCM, Waanders E, et al. Recognition of
genetic predisposition in pediatric cancer patients: an easy-to-use
selection tool. Eur J Med Genet. 2016;59(3):116-125.
21.DiNardo CD, Bannon SA, Routbort M, et al. Evaluation of patients and families with concern for predispositions to hemato- logic malignancies within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk.
2016;16(7):417-428.e2
haematologica | 2021; 106(3)